Neos Therapeutics, Inc. (NASDAQ:NEOS) shares were up 1.6% on Monday . The stock traded as high as $9.35 and last traded at $9.00. Approximately 436,075 shares traded hands during mid-day trading, a decline of 67% from the average daily volume of 1,313,430 shares. The stock had previously closed at $9.15.

Several brokerages have recently issued reports on NEOS. Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, June 10th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Neos Therapeutics in a research report on Tuesday, June 20th. ValuEngine raised shares of Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 20th. Cantor Fitzgerald initiated coverage on shares of Neos Therapeutics in a research note on Monday, July 31st. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Royal Bank Of Canada set a $12.00 target price on shares of Neos Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $13.83.

The stock’s market cap is $259.74 million. The stock’s 50 day moving average price is $8.87 and its 200 day moving average price is $8.87.

Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Tuesday, August 8th. The company reported ($0.83) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The company had revenue of $4.91 million during the quarter. On average, equities research analysts expect that Neos Therapeutics, Inc. will post ($3.10) earnings per share for the current year.

A number of large investors have recently made changes to their positions in NEOS. TIAA CREF Investment Management LLC grew its stake in Neos Therapeutics by 4.9% in the second quarter. TIAA CREF Investment Management LLC now owns 46,853 shares of the company’s stock valued at $342,000 after acquiring an additional 2,168 shares during the period. Rhumbline Advisers increased its holdings in shares of Neos Therapeutics by 13.6% during the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock valued at $149,000 after acquiring an additional 2,441 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Neos Therapeutics by 16.3% during the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock valued at $149,000 after acquiring an additional 3,572 shares in the last quarter. Wells Fargo & Company MN increased its holdings in shares of Neos Therapeutics by 13.0% during the second quarter. Wells Fargo & Company MN now owns 54,253 shares of the company’s stock valued at $396,000 after acquiring an additional 6,223 shares in the last quarter. Finally, UBS Group AG increased its holdings in shares of Neos Therapeutics by 6.1% during the first quarter. UBS Group AG now owns 108,714 shares of the company’s stock valued at $783,000 after acquiring an additional 6,276 shares in the last quarter. Institutional investors and hedge funds own 44.29% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/neos-therapeutics-inc-neos-trading-up-1-6/1606686.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.